Kaplan Fox encourages investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to contact the firm to learn about their legal rights. Aug. 3, 2026 9:00 PM ET Source: Kaplan Fox NEW YORK, NY - August 3, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact NewMediaWire LLC. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 28, 2026 to serve as a lead plaintiff for the purported class. If you have losses NewMediaWire LLC encourage you to contact NewMediaWire LLC to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that on July 27, 2026, before the market opened, the FDA released briefing documents ahead of its AdCom meeting for Capricor's resubmitted Dermamiocel Biologics License Application ("BLA"). Further, the complaint alleges that according to the briefing documents, Capricor made changes to the pre-specified statistical analysis plan ("SAP") and the final version "was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon." On July 27, 2026, Capricor's stock price fell $12.70, or 64%, to close at $7 per share. WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America - the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act - $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

CAPR investors have opportunity to lead Capricor Therapeutics, Inc. securities fraud lawsuit with SBS law. * 3 hrs ago Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. The Duke of Edinburgh attends a DofE award ceremony at Holyrood House CLASS PERIOD: December 17, 2025 to July 26, 2026 DEADLINE: September 28, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages. Mycarrollcountynews also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach Mycarrollcountynews through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor. Media gallery

CAPR stock collapses as FDA slams deramiocel data. TIM BOHEN - UPDATED JUL. 30, 2026, 8:34 AM ET Capricor Therapeutics Inc. shares have been trading down by -51.54 percent amid heightened concern over its latest clinical trial outlook. Key takeaways for CAPR traders. * FDA advisory committee briefing documents for Capricor's lead cell therapy deramiocel questioned the effectiveness data, statistical methodology, and overall benefit-risk profile, including a post-hoc change in the primary endpoint analysis. * Following release of the FDA staff's highly critical briefing materials, Capricor's shares plunged roughly 60-70%, trading around $7.00 at one point and suffering an intraday decline of about 62-65%. * Multiple plaintiffs' law firms, including Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith, have launched or announced investigations into potential securities fraud or investor claims related to Capricor's prior statements about deramiocel's efficacy data and regulatory review. * An analyst from Cantor Fitzgerald characterized the FDA briefing documents on deramiocel as painting an "ugly picture" and raising questions about data integrity, adding to regulatory and litigation concerns around Capricor. Live Update At 08:33:51 EDT: On Thursday, July 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending down by -51.54%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Capricor Therapeutics Inc. just showed traders what a full-blown repricing looks like. CAPR closed near $19.70-$19.80 in late July, then collapsed into the mid-single digits once the FDA briefing documents hit. The daily chart goes from a tight high-teens range to a straight-down move, with CAPR printing around $6.57 after the dust started to settle. The intraday tape backs up the shock. In premarket five-minute candles, CAPR traded as low as the mid-$2s before bouncing toward $3. That kind of 70% gap-down followed by wild premarket swings tells you one thing: forced selling and panic. On the fundamentals, the filings show Capricor running a classic high-burn biotech profile. The company reported a quarterly net loss, negative operating cash flow, and negative free cash flow, while key profitability ratios like pretax margin and returns on equity and assets are deeply in the red. At the same time, CAPR's balance sheet carries a low debt-to-equity ratio and a very high current ratio, meaning liquidity is strong enough for now. For traders, that combination usually means one clear focus: the binary outcome around the lead drug, because the business itself is not funding the story. Why traders are watching CAPR after the FDA shock. CAPR is now a live case study in how fast sentiment can flip when a single asset drives the whole story. The FDA advisory committee briefing documents on deramiocel did more than nitpick; they questioned whether the HOPE-2 and HOPE-3 data provide substantial evidence of effectiveness in Duchenne-related cardiomyopathy and flagged an unfavorable benefit-risk profile. Once those concerns, including post-hoc changes to the primary endpoint and statistical plan, hit the tape, traders wasted no time hitting the sell button. Capricor Therapeutics saw roughly 60-70% of its market value erased in a blink, with CAPR changing hands near $7.00 and even lower in fast markets. The link is direct: FDA staff questioned data handling, methodology, and safety signals such as hypersensitivity and anaphylaxis, and the stock fell about 62-65% intraday on heavy volume. That is the market repricing the probability that deramiocel ever becomes a commercial product. Wall Street commentary lined up with the regulators. An analyst at Cantor Fitzgerald said the FDA documents painted an "ugly picture" and raised data-integrity questions. Meanwhile, multiple firms downgraded CAPR to Neutral and aggressively slashed price targets, signaling that the Street now sees approval in the current form as unlikely. Then comes the legal overhang. Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith have all announced securities-fraud or shareholder-rights investigations tied to deramiocel disclosures and the subsequent plunge in CAPR. For short-term trading, that means recurring headline risk, possible class-action filings, and a management team that may be spending more time with lawyers than on strategic pivots. CAPR has gone from a high-beta biotech play to a deeply damaged story that will likely trade on every new FDA or legal headline. Conclusion. For active traders, CAPR is now in the "broken story" category. The FDA advisory panel briefing documents and a later 9-3 vote that deramiocel's benefits do not outweigh its risks sharply reduce near-term approval odds. When CAPR drops from nearly $20 to the mid-single digits on those headlines, the chart is telling you the market no longer believes the old narrative around deramiocel. Capricor Therapeutics still has cash and a relatively clean balance sheet, but the income statement and cash-flow data show a company dependent on external funding and future drug success, not operating profits. With CAPR facing both regulatory pushback and a growing swarm of securities-law investigations, dilution and restructuring risk move higher on every timeframe traders care about. That does not mean CAPR stops moving. In this kind of high-volatility, low-trust environment, sharp dead-cat bounces and painful short squeezes are common. These kinds of moves can tempt even experienced traders to chase spikes and abandon discipline. As Tim Bohen, lead trainer with StocksToTrade says, "I never chase price. The best opportunities allow me to enter on my terms, not when I'm feeling pressured." But they are trading setups, not safety nets. As Tim Sykes likes to remind his students, "Volatility is opportunity, but only if you respect the risk and cut losses quickly." For anyone watching CAPR now, the homework is simple: track every FDA and court update, understand that deramiocel is no longer a clean catalyst, and treat every bounce as a trade, not a promise. This article is for educational and research purposes only and is not investment advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. One must-buy stock for Monday. Want to start next week off with a big win? Its new algorithm may have just uncovered a new dirt-cheap stock with a great chance of moving +100% or more this Monday. ...One ticker... ...One trade... ...One MONSTER move... All you have to do is make this one trade on Monday. While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day. And StocksToTrade, Inc. think this new pick could be just as big. But if StocksToTrade, Inc. is right, it may move FAST...